Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

cGMP-PDE inhibitors revealed by Fujisawa

Dec. 11, 1996

P&U anticipates filing for urinary incontinence treatment soon

Dec. 10, 1996

Merck & Co. reveals new agents for BPH

Dec. 10, 1996

VIP analogs and derivatives claimed for smooth muscle relaxation

Dec. 9, 1996

Sepracor gets go-ahead for U.S. clinical trials on (S)-oxybutynin

Dec. 6, 1996

Synsorb Pk licensed to major Japanese pharmaceutical company

Dec. 4, 1996

Chugai starts phase I clinical trials with phosphate binder

Dec. 4, 1996

Negative clinical results reported for aromatase inhibitor in BPH

Nov. 29, 1996

Kissei begins overseas development of BPH treatment agent

Nov. 21, 1996

Kyorin claims cholinergic agents

Nov. 21, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...